The No Surprises Act, enacted as part of the Consolidated Appropriations Act , includes transparency provisions requiring group health plans to report information on prescription drugs and healthcare spending to the departments of Labor, Health and Human Services and the Treasury (“the departments”). This requirement applies to group health plans and health insurance issuers in the individual and group markets but does not apply to account-based plans and excepted benefits. This reporting process is referred to as the prescription drug data collection (or “RxDC report”). The first RxDC report was due Dec. 27, 2022 (covering data for 2020 and 2021); however, the departments provided a submission grace period through Jan. 31, 2023, for this first report. Subsequent RxDC reports are due by June each year covering data for the previous calendar year. According to interim final rules , employers may use issuers, third-party administrators, pharmacy benefit managers or other third parties t...

The Consolidated Appropriations Act, 2021 enacted the No Surprises Act with the aim of bringing transparency to the healthcare industry. The NSA includes several provisions, including prescription drug data collection (RxDC report). The requirement applies to group health plans and health insurance issuers in the individual and group markets. The NSA requires health insurance issuers and group health plans to report information on prescription drugs and healthcare spending to the departments of Labor, Health and Human Services, and the Treasury. This means that insurers and group health plans must provide information such as the total spending on prescription drugs, the number of individuals enrolled in the plan or issuer, and the total cost-sharing amounts paid by enrollees. Check out our Compliance Overview to discover all the requirements and deadlines for prescription drug reporting. For more information about  employee benefits, our services and products,  contact HANYS ...